Download PDF
Onkologische Welt 2010; 01(04): 179-181
DOI: 10.1055/s-0038-1632842
Kongressnachlese Senologie 2010
Schattauer GmbH

Adjuvante endokrine Therapie des Mammakarzinoms

Peter Henning Dr.
Further Information

Publication History

Publication Date:
03 February 2018 (online)

Also available at
    Permissions and Reprints

 

 

  • Literatur

  • 1 Arbeitsgemeinschaft Gynäkologische Onkologie e.V. Kommission Mamma. Empfehlungen Gynäkologische Onkologie. Februar 2010 http://www.ago-online.org/index.php?.site=mamma_guide&lang=de
    PubMed
  • 2 Bliss JM. et al. 32th. Annual San Antonio Breast Cancer Symposium. 2009 Oral Presentation #12.
    PubMedGoogle Scholar
  • 3 Hershman DL. et al. Effect of early discontinuation and nonadherence to adjuvant hormone therapy on mortality in women with breast cancer. 2010 ASCO Annual Meeting. J Clin Oncol 2010; 28 Suppl.; Abstr 578 15s.
    CrossrefGoogle Scholar
  • 4 Dent SF. et al. Breast Cancer Res Treat. 2007 106 (Suppl. 1; Abstr. 2079).
    PubMedGoogle Scholar
  • 5 Hadji P. et al. Ann Oncol 2009; 20: 1203-1209.
    CrossrefPubMed
  • 6 Hadji P. et al. Breast 2009; 18: 159-164.
    CrossrefPubMed
  • 7 Coleman R. et al. 31st. Annual San Antonio Breast Cancer Symposium. 2008 Abstract 1128.
    PubMedGoogle Scholar
  • 8 Ortmann O. et al. Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor?. Recommendations of an expert panel. Cancer Treatment Reviews. Published online 1. July 2010.
    Google Scholar